Thromboembolic events don't appear higher in vaccinated population, EMA says
As of lunchtime on Tuesday, 11 European countries had halted the rollout of COVID-19 Vaccine AstraZeneca after a number of cases of blood clots.
Experts from the World Health Organization and the European Medicines Agency (EMA) are meeting to review the vaccine, although both agencies, along with the UK regulator, have said there is no evidence of a link to the instances of blood clots.
"Many thousands of people develop blood clots annually in the European Union for different reasons"A press briefing is due to be held by the EMA later on Tuesday to provide an update on findings from the EMA’s investigations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze